Compare HCAI & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAI | ONCO |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.0M |
| IPO Year | 2023 | 2021 |
| Metric | HCAI | ONCO |
|---|---|---|
| Price | $2.01 | $0.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 5.0M |
| Earning Date | 09-30-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.13 | $0.09 |
| 52 Week High | $25.99 | $644.00 |
| Indicator | HCAI | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 47.34 |
| Support Level | $0.24 | $0.09 |
| Resistance Level | $5.16 | $1.02 |
| Average True Range (ATR) | 0.39 | 0.07 |
| MACD | 0.30 | 0.02 |
| Stochastic Oscillator | 53.46 | 60.13 |
Huachen AI Parking Management Technology Holding Co Ltd a comprehensive electric vehicle charging solutions and equipment structural parts provider. The company has determined that it has only one reported operating segments. It also used to provide customized smart parking solutions to optimize efficiency in limited parking spaces, covering smart cubic parking garage design, cubic parking equipment manufacturing, sales, installation, and maintenance. To cater the customers different parking needs, It manufacture and offer various cubic parking garage products by employing various working principles, such as lifting and shifting, convenient lifting, vertical circulation, vertical lifting, plane moving, alley stacking, multi-layer cycle, horizontal cycle, and car lift.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.